<DOC>
	<DOCNO>NCT02348632</DOCNO>
	<brief_summary>This Phase 3 study assess long-term safety maintenance efficacy JZP-110 subject complete Study 14-002 , 14-003 , 14-004 , 15-004 , 15-005 , ADX-N05 201 , ADX-N05 202 .</brief_summary>
	<brief_title>`` A Long-Term Safety Study JZP-110 Treatment Excessive Sleepiness Subjects With Narcolepsy OSA ''</brief_title>
	<detailed_description />
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Narcolepsy</mesh_term>
	<criteria>Major 1 . Subject meet one following : 1 . Completed Study 14002 14003 ( Group A ) 2 . Completed Study 14004 , 15004 , 15005 , ADXN05 201 ADXN05 202 ( Group B ) 2 . Body mass index 18 &lt; 45 kg/m2 3 . Consent use medically acceptable method contraception 4 . Willing able provide write informed consent Major 1 . Female subject pregnant , nursing , lactate 2 . Any clinically relevant medical , behavioral , psychiatric disorder narcolepsy OSA associate excessive sleepiness 3 . History presence bipolar disorder , bipolar related disorder , schizophrenia , schizophrenia spectrum disorder , psychotic disorder accord DSM5 criterion 4 . Presence acutely unstable medical condition , behavioral psychiatric disorder ( include active suicidal ideation ) , surgical history could affect safety subject interfere study efficacy safety assessment , ability subject complete trial per judgment Investigator 5 . History bariatric surgery within past year history rouxeny procedure 6 . Presence history significant cardiovascular disease 7 . Use counter ( OTC ) prescription medication could affect evaluation excessive sleepiness 8 . Received investigational drug JZP110 past 30 day five halflives ( whichever longer ) 9 . History phenylketonuria ( PKU ) history hypersensitivity phenylalaninederived product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>